Evidence map›Paper›PMID 40619591›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025

Adaptive Antioxidant Nanomedicines Inhibit Ferroptosis in Renal Tubular Epithelial Cells to Alleviate Diabetic Kidney Disease.

Zerun Liu, Ting Huang, Ying Hong, Yuqi Yang, Wensheng Chen, Qingtao Zeng, Qiaohui Chen, Yongqi Yang, Xiaohong Ying, Wan Zeng and 6 more

Abstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Zerun LiuDepartment of Pharmacy, Xiangya Hospital, Central South University, Changsha, 410008, China.
Ting HuangDepartment of Pharmacy, Xiangya Hospital, Central South University, Changsha, 410008, China.
Ying HongDepartment of Pharmacy, Xiangya Hospital, Central South University, Changsha, 410008, China.
Yuqi YangDepartment of Pharmacy, Xiangya Hospital, Central South University, Changsha, 410008, China.
Wensheng ChenDepartment of Pharmacy, Xiangya Hospital, Central South University, Changsha, 410008, China.
Qingtao ZengDepartment of Pharmacy, Xiangya Hospital, Central South University, Changsha, 410008, China.
Qiaohui ChenXiangya School of Pharmaceutical Sciences, Central South University, Changsha, 410078, China.
Yongqi YangXiangya School of Pharmaceutical Sciences, Central South University, Changsha, 410078, China.
Xiaohong YingXiangya School of Pharmaceutical Sciences, Central South University, Changsha, 410078, China.
Wan ZengXiangya School of Pharmaceutical Sciences, Central South University, Changsha, 410078, China.
Ziyu WuXiangya School of Pharmaceutical Sciences, Central South University, Changsha, 410078, China.
Tianjiao ZhaoXiangya School of Pharmaceutical Sciences, Central South University, Changsha, 410078, China.
Xuesi WanDepartment of Endocrinology and Diabetes Center, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China.
Jianlin ChenPancreatic Surgery, Xiangya Hospital, Central South University, Changsha, 410008, China.
Kelong AiXiangya School of Pharmaceutical Sciences, Central South University, Changsha, 410078, China.ORCID https://orcid.org/0000-0002-9863-8963
Qiong HuangDepartment of Pharmacy, Xiangya Hospital, Central South University, Changsha, 410008, China.

Funding

Central South University Research Program of Advanced Interdisciplinary Studies 2023QYJC017Fundamental Research Funds for the Central Universities of Central South University 1053320221664:1053320221919:1053320232303Key Research and Development Program of Hunan Province 2024JK2114Key Research Project of Ningxia Hui Autonomous Region of China 2023BEG02038National Natural Science Foundation of China 82100895:81974508National Natural Science Foundation of China 82373871Project Program of National Clinical Research Center for Geriatric Disorders 2023LNJJ12
6 · The paper itself

Abstract

Diabetic kidney disease (DKD) imposes a heavy medical burden worldwide due to the lack of effective treatment. High levels of mtROS and mitochondrial damage in the renal tubules are the initiating and core factors driving the progression of DKD. However, the effectiveness of current antioxidant drugs is greatly limited, mainly due to the difficulty of simultaneously breaching the glomerular barrier and targeting tubular mitochondria, as well as their limited ability to sustain treatment of chronic DKD. Here, this study reports a Se embedded adaptive antioxidant nanodrug (AAN) with negative surface charge and high mitochondrial targeting that can pass through the renal tubules and be highly enriched in the affected renal tubular mitochondria in DKD. AAN can eliminate mtROS to release soluble Se, which is then converted into the key bioactive enzymes -GPX4, effectively inhibiting ferroptosis and protecting mitochondria by exerting adaptive antioxidant effects. In the DKD mouse model, AAN treatment can effectively restore renal function, and the therapeutic effect at a dose of 10 mg kg

Indexed as

AntioxidantsDiabetic NephropathiesEpithelial CellsFerroptosisKidney TubulesNanomedicineAnimalsDiabetes Mellitus, ExperimentalDisease Models, AnimalMaleMiceMice, Inbred C57BLMitochondriaAntioxidantsadaptive antioxidant nanodrugdiabetic kidney diseaseferroptosisGPX4mtROS

Identifiers

PMID40619591
PMCPMC12499382

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.